Cambridge Healthtech’s Inaugural
Expanding Dx Portfolio for Veterinary Applications
Repurposing Diagnostics from Humans to All Species of Animals
August 20, 2019
As the point-of-care testing (POCT) sector is rapidly growing, companies are looking for new market opportunities and ways to increase revenue. With less reimbursement and regulation hurdles to overcome as well as similarities in biology, human diagnostics
companies, particularly those in the POCT space, can look to the veterinary space to join the fray. Cambridge Healthtech Institute is proud to offer Expanding Dx Portfolio for Veterinary Applications, where we will discuss ways to repurpose human
diagnostic platforms for companion and production animals.
Final Agenda
TUESDAY, AUGUST 20
7:30 am Registration and Morning Coffee
8:30 Chairperson’s Opening Remarks
Chris Myatt, Founder & CEO, MBio Diagnostics, Inc.
8:40 Case Study: Why Go into Vet DX?
Chris Myatt, Founder &
CEO, MBio Diagnostics, Inc.
I will discuss the benefits and challenges of designing, manufactoring, and testing human and animal microfluidic diagnostics platforms.
9:10 INTERACTIVE PANEL DISCUSSION: Identifying Current Trends and Opportunities in Veterinary Diagnostics
Moderator: Chris Myatt,
Founder & CEO, MBio Diagnostics, Inc.
Panelists: Stephane Shu Kin So, PhD, MBA, CLP, Associate Director, Research Alliances, External Innovation, Zoetis
Chand Khanna, DVM,
PhD, DACVIM (Onc), DACVP (Hon), CSO, Ethos Veterinary Health, President, Ethos Discovery
This panel will discuss the trends in precision medicine for companion and livestock animals, the veterinary reference lab landscape and how to deliver advanced veterinary diagnostics.
10:10 Coffee Break in the Exhibit Hall with Poster Viewing
10:55 Chairperson’s Remarks
Chand Khanna, DVM, PhD, DACVIM (Onc), DACVP (Hon), Chief Science Officer, Ethos Veterinary Health, President, Ethos Discovery
11:00 Exploiting Quorum Sensing to Identify Bacterial Infections
Edgar D. Goluch, PhD, Founder & CEO, QSM Diagnostics, Inc.
Real-time measurement of molecules secreted by bacterial cells provides important insights about the species that are present in a sample as well as what the cells are doing. My research for the last nine years has focused on studying quorum sensing molecules
and other metabolites made by Pseudomonas aeruginosa in various samples and environments. We use low-cost sensors that allow us to measure the amounts and production rates of these chemicals, which are secreted by all species of bacterial
cells, in real time at physiologically relevant concentrations. This talk will describe our findings and introduce you to the platform technology that we are developing at QSM Diagnostics for immediate identification and continuous monitoring of bacteria
causing urinary tract infections in animals and humans.
11:30 INTERACTIVE PANEL DISCUSSION: Bridging the Gap between Clinical Vets and Diagnostics Companies
Moderator: Chand Khanna,
DVM, PhD, DACVIM (Onc), DACVP (Hon), CSO, Ethos Veterinary Health, President, Ethos Discovery
Panelists: Edgar D. Goluch, PhD, Founder & CEO, QSM Diagnostics, Inc.
12:30 pm End of Expanding Dx Portfolio for Veterinary Applications
1:00 Cookie & Refreshment Break in the Exhibit Hall with Poster Viewing
Recommended Short Course*
SC15: Microfluidics and Lab-on-a-Chip Devices for POCT: Technologies and Commercialization
Chris Myatt, Founder & CEO, MBio Diagnostics, Inc.
Additional Speakers to be Announced
This short course will provide an overview of microfluidic techniques, including valved and valve-less devices, pumped systems, and capillary flow approaches. Practical examples will keep the discussion grounded in the realization of commercializable
devices. We will discuss engineering approaches to enhance the advantages and minimize the challenges. Throughout, the science will be linked to the commercial case for these devices, including a full discussion of a recent success story of a centrifugal
microfluidic molecular assay system.
*Separate registration required.